Literature DB >> 12761260

Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients.

Kumeo Ono1, Akiyasu Tsuchida, Hironobu Kawai, Hidenori Matsuo, Ryouji Wakamatsu, Akira Maezawa, Shintarou Yano, Tomoyuki Kawada, Yoshihisa Nojima.   

Abstract

A reduction in ankle-brachial BP index (ABPI) is associated with generalized atherosclerotic diseases and predicts cardiovascular mortality and morbidity in several patient populations. However, a large-scale analysis of ABPI is lacking for hemodialysis (HD) patients, and its use in this population is not fully validated. A cohort of 1010 Japanese patients undergoing chronic hemodialysis was studied between November 1999 and May 2002. Mean age at entry was 60.6 +/- 12.5 yr, and duration of follow-up was 22.3 +/- 5.6 mo. Patients were stratified into five groups (< 0.9, > or = 0.9 to < 1.0, > or = 1.0 to < 1.1, > or = 1.1 to < 1.3, and > or = 1.3) by ABPI measured at entry by an oscillometric method. The frequency distribution of ABPI was 16.5% of patients < 0.9, 8.6% of patients > or = 0.9 to < 1.0, 16.9% of patients 1.0 > or = to < 1.1, and 47.0% of patients > or 1.1 to < 1.3, whereas 10.9% of patients had an abnormally high ABPI (> or = 1.3). The relative risk of a history of diabetes mellitus (DM), cardiovascular, and cerebrovascular disease was significantly higher in patients with lower ABPI than those with ABPI > or = 1.1 to <1.3. During the study period, 77 cardiovascular and 41 noncardiovascular fatal events occurred. On the basis of Cox proportional hazards regression analysis, ABPI emerged as a strong independent predictor of all-cause and cardiovascular mortality. After adjustment for confounding variables, the hazard ratio (HR) for ABPI < 0.9 was 4.04 (95% confidence interval, 2.38 to 6.95) for all-cause mortality and 5.90 (2.83 to 12.29) for cardiovascular mortality. Even those with modest reductions in the ABPI (> or = 0.9 to <1.1) appeared to be at increased risk. Patients having abnormally high ABPI (> or = 1.3) also had poor prognosis (HR, 2.33 [1.11 to 4.89] and 3.04 [1.14 to 8.12] for all-cause and cardiovascular mortality, respectively). Thus, the present findings validate ABPI as a powerful and independent predictor for all-cause and cardiovascular mortality among hemodialysis patients.

Entities:  

Mesh:

Year:  2003        PMID: 12761260     DOI: 10.1097/01.asn.0000065547.98258.3d

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  63 in total

Review 1.  Abnormal ankle-brachial index and risk of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis.

Authors:  Hai-Yan Chen; Fang Wei; Li-Hua Wang; Zhe Wang; Jia Meng; Hai-Bo Yu; Rui-Ning Zhang; Gui-Jiang Sun; Ai-Li Jiang; Lin Wang
Journal:  J Nephrol       Date:  2017-02-15       Impact factor: 3.902

2.  Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study.

Authors:  Knut Kröger; Andreas Stang; Jana Kondratieva; Susanne Moebus; Eva Beck; Axel Schmermund; Stefan Möhlenkamp; Nico Dragano; Johannes Siegrist; Karl-Heinz Jöckel; Raimund Erbel
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

3.  5(th) Asian PAD Workshop.

Authors: 
Journal:  Ann Vasc Dis       Date:  2014

4.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

5.  Usefulness of baseline obesity to predict development of a high ankle brachial index (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Geoffrey H Tison; Chiadi E Ndumele; Gary Gerstenblith; Matthew A Allison; Joseph F Polak; Moyses Szklo
Journal:  Am J Cardiol       Date:  2011-03-04       Impact factor: 2.778

6.  Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients.

Authors:  Szu-Chia Chen; Jer-Ming Chang; Shang-Jyh Hwang; Jer-Chia Tsai; Chuan-Sheng Wang; Hsiu-Chin Mai; Feng-Hsien Lin; Ho-Ming Su; Hung-Chun Chen
Journal:  Clin J Am Soc Nephrol       Date:  2009-01       Impact factor: 8.237

7.  Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  J Dawn Abbott; Manuel S Lombardero; Gregory W Barsness; Ivan Pena-Sing; L Virginia Buitrón; Premranjan Singh; Gail Woodhead; Jean-Claude Tardif; Sheryl F Kelsey
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

8.  Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study.

Authors:  Mireia Junyent; Montserrat Martínez; Mercè Borràs; Blai Coll; Jose Manuel Valdivielso; Teresa Vidal; Felipe Sarró; Jordi Roig; Lourdes Craver; Elvira Fernández
Journal:  BMC Nephrol       Date:  2010-07-07       Impact factor: 2.388

Review 9.  Medial arterial calcification in diabetes and its relationship to neuropathy.

Authors:  W J Jeffcoate; L M Rasmussen; L C Hofbauer; F L Game
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

10.  Serum ferritin is associated with progression of peripheral arterial disease in hemodialysis patients.

Authors:  Chen-Tung Lien; Kao-Chang Lin; Yueh-Feng Tsai; Lai-King Yu; Li-Hsueh Huang; Chien-An Chen
Journal:  Clin Exp Nephrol       Date:  2014-12-24       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.